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1Division of Infectious Diseases, Department of Medicine, 2Department of Surgery, and 3Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine,  
St. Louis, Missouri; and 4HealthCore, Inc., Wilmington, Delaware 
Background. There are limited data on risk factors for surgical site infection (SSI) after open or laparoscopic cholecystectomy.
Methods. A retrospective cohort of commercially insured persons aged 18–64  years was assembled using International 
Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) procedure or Current Procedural Terminology, 4th edition 
codes for cholecystectomy from December 31, 2004 to December 31, 2010. Complex procedures and patients (eg, cancer, end-stage 
renal disease) and procedures with pre-existing infection were excluded. Surgical site infections within 90 days after cholecystectomy 
were identified by ICD-9-CM diagnosis codes. A Cox proportional hazards model was used to identify independent risk factors for 
SSI.
Results. Surgical site infections were identified after 472 of 66 566 (0.71%) cholecystectomies; incidence was higher after open 
(n = 51, 4.93%) versus laparoscopic procedures (n = 421, 0.64%; P < .001). Independent risk factors for SSI included male gender, pre-
operative chronic anemia, diabetes, drug abuse, malnutrition/weight loss, obesity, smoking-related diseases, previous Staphylococcus 
aureus infection, laparoscopic approach with acute cholecystitis/obstruction (hazards ratio [HR], 1.58; 95% confidence interval 
[CI], 1.27–1.96), open approach with (HR, 4.29; 95% CI, 2.45–7.52) or without acute cholecystitis/obstruction (HR, 4.04; 95% CI, 
1.96–8.34), conversion to open approach with (HR, 4.71; 95% CI, 2.74–8.10) or without acute cholecystitis/obstruction (HR, 7.11; 
95% CI, 3.87–13.08), bile duct exploration, postoperative chronic anemia, and postoperative pneumonia or urinary tract infection.
Conclusions. Acute cholecystitis or obstruction was associated with significantly increased risk of SSI with laparoscopic but not 
open cholecystectomy. The risk of SSI was similar for planned open and converted procedures. These findings suggest that stratifica-
tion by operative factors is important when comparing SSI rates between facilities.
Keywords. administrative health claims data; cholecystectomy; risk factors; surgical site infection.
 
Surgical site infection (SSI) is the most common healthcare-as-
sociated infection [1, 2] and contributes to increased length of 
hospitalization and healthcare costs [1, 3]. Cholecystectomy is 
the most commonly performed abdominal surgery and one of 
the most common ambulatory procedures performed in the 
United States [4, 5]. The incidence of SSI is higher after open 
versus laparoscopic cholecystectomy, with reported SSI rates 
after open cholecystectomy ranging from 1.1% to 8.4% [6–16] 
versus 0.3% to 3.4% after laparoscopic cholecystectomy [6–16].
Although open cholecystectomy has been consistently asso-
ciated with higher risk of SSI [6, 7, 10, 13, 17–19], other risk 
factors for SSI have not been as well established. Older age [6, 
7, 18, 20, 21], male gender [6, 7, 13], longer duration of sur-
gery [6, 13, 17, 18, 20], multiple surgical procedures [6, 20], 
higher severity of illness [6, 8, 10, 17, 18], and contaminated/
infected wound class [6, 8, 17, 18] have been reported as inde-
pendent risk factors for SSI after cholecystectomy. The impact 
of other patient-, operative-, and postoperative-level factors 
on SSI risk after cholecystectomy has not been well studied, 
and it may be important for risk stratification in facilities with 
different patient case mix. Because the majority of cholecys-
tectomy operations are performed in ambulatory surgery, we 
sought to investigate risk factors for SSI in patients without 
serious underlying medical conditions after cholecystectomy 




We conducted a retrospective cohort study using the 
HealthCore Integrated Research Database, which includes 
all fully adjudicated claims submitted for reimbursement 
from providers, facilities, and outpatient pharmacies linked 
to private health plan enrollment information, as described 
previously [22].
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Cholecystectomy Patient Population
We identified cholecystectomy procedures performed at a 
hospital on an inpatient or outpatient basis or at a freestand-
ing ambulatory surgery center (ASC) using International 
Classification of Diseases, 9th Revision, Clinical Modification 
(ICD-9-CM) and Current Procedural Terminology, 4th edi-
tion (CPT-4) procedure codes from facility and provider claims 
between December 31, 2004 and December 31, 2010 among 
members aged 18–64  years (Supplementary Appendix 1). To 
capture comorbidities, we excluded members lacking prescrip-
tion drug coverage and/or 365 days of prior insurance enroll-
ment before cholecystectomy.
Exclusion of Erroneous Claims for Cholecystectomy
We excluded erroneous claims (ie, facility claims with appar-
ent CPT-4, Healthcare Common Procedure Coding System, or 
UB-04 revenue codes truncated to 4 digits and populated in the 
fields reserved for ICD-9-CM procedure codes) as described 
previously [22]. We also excluded claims in which a cholecys-
tectomy procedure code was present only on 1 line on a single 
claim, with no other claims on the same date.
Exclusion of Complicated Patients and Procedures
Because our focus was on SSI risk in patients who would be eli-
gible to have their procedure performed in ambulatory surgery, 
we excluded cholecystectomy procedures performed in medically 
complicated patients (ie, coded for cancer, chemotherapy, end-stage 
renal disease, or prior organ transplant) from 30 days (365 for organ 
transplant) before to 7 days after cholecystectomy (Supplementary 
Appendix 1). We also excluded complex operations, defined as 
those in which motor vehicle accident, fracture involving the skull 
or trunk, abdominal compartment syndrome, or gunshot wound 
were coded on the same claim as the cholecystectomy or on a 
contemporaneous ambulance or emergency department claim, 
and other complicated procedures, as defined in Supplementary 
Appendix 1.  We also excluded cholecystectomy procedures per-
formed on the day of or after another surgical procedure during 
the same hospitalization; additional surgical procedures were iden-
tified using the procedure codes used for SSI surveillance by the 
National Healthcare Safety Network (NHSN) [23] and additional 
CPT-4 codes for abdominal surgeries (Supplementary Appendix 
1). We did not exclude a cholecystectomy if another procedure 
occurred after the cholecystectomy, because these might have been 
performed as a result of a complication of the cholecystectomy. 
Finally, we excluded cholecystectomies performed on or after day 3 
of an inpatient hospital stay because these patients would not have 
had the opportunity for surgery in an ambulatory facility.
Surgery Date and Classification of Cholecystectomy
All provider and facility claims for cholecystectomy within 
7 days were collapsed into a single surgery due to the potential 
for inaccuracy in dates [24]. When there was more than one date 
within 7  days coded for cholecystectomy, we compared facil-
ity and provider surgery dates and incorporated supplemental 
evidence from other unique providers to determine the most 
likely surgery date (Supplementary Appendix 1). After consoli-
dating service dates, if there was still more than 1 claim date for 
cholecystectomy within an individual person, we used the first 
claim date as the study procedure date.
We classified the cholecystectomy as laparoscopic or open 
based on ICD-9-CM procedure and CPT-4 codes from the pro-
vider and facility (Supplementary Appendix 1). As described 
previously [22], to obtain more accurate SSI rates by surgical 
approach, we excluded cholecystectomy procedures that were 
coded by a provider- or facility-only, or when the provider and 
facility coded discordant surgical approaches.
Identification of Surgical Site Infection
Surgical site infections recorded 2–90  days after cholecystec-
tomy were identified using ICD-9-CM diagnosis codes from 
inpatient and outpatient facilities and provider claims. We did 
not include claims with SSI diagnosis codes from service loca-
tions inconsistent with a provider diagnosis of SSI (eg, home, 
ambulance) and claims with CPT-4 codes for laboratory ser-
vices (88104-88399) to avoid “rule-out” diagnoses. Persons 
with claims for SSI, peritonitis, retroperitoneal infection, or 
septicemia (ICD-9-CM diagnosis 038.0–0.38.9, 790.7) between 
30  days before to 1  day after the cholecystectomy date were 
excluded due to pre-existing infection.
The diagnosis codes used to identify SSIs included postopera-
tive wound infection (998.5, 998.51, 998.59), peritonitis (567.2–
567.29, 567.9), and retroperitoneal infection (567.3–567.39). 
We also considered a diagnosis code of cellulitis of the trunk 
(682.2) on the same claim as a CPT-4 code for incision and 
drainage (10060, 10061, 10180, 11005, 49020, 49021, 49040, 
49041, 49060, 49061)  as evidence of SSI, consistent with the 
NHSN definition of SSI [23]. The ICD-9-CM diagnosis code for 
unspecified cellulitis (682.9) was also used to identify SSIs, but 
only if it was on the same claim as an abdomen-specific CPT-4 
code for incision and drainage (11005, 49020, 49021, 49040, 
49041, 49060, 49061), or if it was coded on the same claim as 
an incision and drainage procedure by the operating surgeon. 
We defined the SSI onset date as described previously [25]. We 
categorized SSIs as serious if they were coded during an inpa-
tient admission or within 14 days of a laparotomy (ICD-9-CM 
procedure 54.11, 54.12, 54.19; CPT-4 49000, 49002) or incision 
and drainage procedure (as per codes defined above).
We identified SSIs up to 90  days after surgery, with earlier 
censoring for the end of insurance enrollment or the day after 
subsequent abdominal surgery. We excluded nonabdomen-spe-
cific ICD-9-CM diagnosis codes for SSI (eg, 998.59) if the code 
was first recorded after a nonabdominal NHSN surgery. We 
extended surveillance beyond the standard NHSN definition of 
symptom onset within 30 days because an SSI is not detectable 
in claims data until the patient presents for care, which could be 
delayed from symptom onset. In addition, previous work has 
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a large proportion of infections, depending on the procedure 
[26].
Identification of Risk Factors for Surgical Site Infection 
We obtained patient age and sex from enrollment files. Patient 
home zip code was matched to year 2000 census median house-
hold income [27] to determine income quartile and linked 
to the 2006 National Center for Health Statistics (NCHS) 
urban-rural classification scheme [28] through a 5-digit Federal 
Information Processing Standard code to determine patient 
urban-rural status.
Patient comorbidities and postoperative risk factors were 
identified using ICD-9-CM diagnosis codes [29], ICD-9-CM/
CPT-4 procedure codes, and outpatient prescription drug 
claims. All inpatient facility claims were included; we excluded 
provider and outpatient facility claims containing only CPT-4 
or UB-04 revenue codes for pharmacy, diagnostic radiology/
cardiology/pulmonology, clinical laboratory, physical/occu-
pational therapy, speech pathology, or ambulance services, to 
increase the likelihood that the diagnosis was assigned by a cli-
nician. One or more inpatient claim(s) or ≥2 provider or outpa-
tient facility claims from −365 to + 7 days after cholecystectomy 
were required to establish the diagnosis of most comorbidities 
(Supplementary Appendix 2)  [30]. Postoperative risk factors 
were restricted to those factors coded before SSI.
We included cholecystectomy-related diagnoses on the same 
claim as the cholecystectomy procedure and concurrent pro-
cedures as potential operative risk factors (Supplementary 
Appendix 2). Conversion to an open procedure was defined 
based on the ICD-9-CM diagnosis code for laparoscopic to open 
conversion in patients coded for open cholecystectomy; if the 
provider and facility coded a laparoscopic cholecystectomy, we 
assumed the conversion code referred to another procedure on 
the same claim because the conversion diagnosis code is not spe-
cific to cholecystectomy.
We used the American Hospital Association (AHA) Annual 
Survey of Hospitals (Health Forum, LLC, Chicago, IL) and the 
Outpatient Surgery Center Profiling Solution data (IMS Health, 
Plymouth Meeting, PA) to determine whether the cholecystec-
tomy was performed at a hospital or freestanding ASC. These 
sources were matched to the facility where the cholecystectomy 
was performed using National Provider Identifier codes (when 
available) or facility name and address fields. Among facilities 
matching to a hospital in the AHA survey, determination of 
inpatient or outpatient procedure was based on an inpatient 
designation by the facility for admissions with length of stay 
of 1 day or inpatient designation by the facility or provider for 
admissions with length of stay greater than 1 day. Number of 
beds, medical school affiliation, residency program, and own-
ership were captured from the AHA data for hospitals, whereas 
number of surgical procedures, urban location of facility, and 
region in the United States were available for hospitals and 
ASCs. Urban-rural location of the facility was available in the 
AHA data directly; we used the NCHS urban-rural classifica-
tion scheme linked to ASC zip code for the IMS Health data.
Statistical Analysis
We used univariate and multivariable Cox proportional hazards 
models to examine risk factors for SSI, and we accounted for 
censoring before the 90-day follow-up period. For multivariable 
models, backward selection was used with P <  .05 as the cutoff 
for inclusion among variables with P <  .2 in univariate models. 
We assessed multicollinearity by examining the tolerance values 
in each model to ensure independence of explanatory variables. In 
the event of multicollinearity, we considered model performance 
(C-statistic) to determine which variable to use in the final model. 
Post hoc testing was performed to determine whether related risk 
factors had significantly different hazard ratios (HRs) in the multi-
variable model. As sensitivity analyses to determine the robustness 
of our model, we developed models for early SSI (within 30 days of 
surgery) and serious SSI. All data management and analyses were 
performed using SAS version 9.3 (SAS Institute Inc., Cary, NC). 
This study was approved by the Washington University Human 
Research Protection Office with a waiver of informed consent.
RESULTS
A total of 160 817 cholecystectomy patients met initial eligi-
bility criteria during the 7-year study period. The number of 
patients was reduced to 66 566 after removing procedures 
coded by either provider or facility alone (n = 10 738), proce-
dures performed at the time of another abdominal operation 
(n  =  15 698), procedures performed after the second day of 
hospitalization or at the same time or after another NHSN sur-
gery (n = 14 232), procedures in medically complicated patients 
(n = 5622), procedures with discordant coding for open versus 
laparoscopic approach (n = 727), procedures performed at the 
time of pre-existing infection (n = 753), and patients without 
prescription drug coverage (n = 5204) or without 1 year of prior 
insurance coverage (n = 41 277).
Over 98% of the cholecystectomy procedures were per-
formed laparoscopically (65 532 of 66 566). Of the 1034 open 
procedures, 499 were planned open procedures and 535 were 
laparoscopic converted to open procedures. Seventy-five per-
cent of operations were performed in females, and the median 
age at time of surgery was 45 years (range 18–64). Persons who 
had a laparoscopic procedure were more likely to be female 
and younger than those with open cholecystectomy (P < .001). 
Most operations were performed as same day surgery in a hos-
pital (58%) or during an inpatient hospital admission (16%). 
Planned open or converted procedures were more likely than 
laparoscopic procedures to be performed during an inpatient 
hospitalization (861 [83.3%] vs 15 586 [23.8%]; P < .001).
Four hundred seventy-two surgical site infections were iden-
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Table 1. Univariate Cox Proportional Hazards Model of Risk Factors for SSI After Cholecystectomya
Variable Category SSI n (%) No SSI  n (%) P Hazards Ratio (95% CI)
Total 472 66 094
Patient factors
Demographics
Age 18–25 years 19 (4.0) 4675 (7.1) .008 1.00
26–30 years 40 (8.5) 5742 (8.7) 1.71 (0.99–2.95)
31–35 years 53 (11.2) 6962 (10.5) 1.86 (1.10–3.14)
36–40 years 48 (10.2) 8160 (12.3) 1.44 (0.84–2.44)
41–45 years 49 (10.4) 9157 (13.9) 1.31 (0.77–2.22)
46–50 years 72 (15.3) 9604 (14.5) 1.83 (1.10–3.03)
51–55 years 73 (15.5) 9054 (13.7) 1.97 (1.19–3.26)
56–60 years 74 (15.7) 7800 (11.8) 2.31 (1.39–3.82)
61–64 years 44 (9.3) 4940 (7.5) 2.18 (1.27–3.73)
Male 167 (35.4) 16 609 (25.1) <.001 1.63 (1.35–1.97)
Comorbidities/Medications
Anticoagulopathy drugs n < 10 437 (0.7) .107 1.94 (0.87–4.34)
Blood loss anemia 13 (2.8) 660 (1.0) <.001 2.80 (1.61–4.86)
Chronic anemia 36 (7.6) 1417 (2.1) <.001 3.75 (2.67–5.27)
Congestive heart failure 22 (4.7) 1314 (2.0) <.001 2.41 (1.57–3.70)
Depression 30 (6.4) 2953 (4.5) .048 1.45 (1.00–2.10)
Diabetes mellitus 79 (16.7) 5835 (8.8) <.001 2.07 (1.63–2.64)
Drug abuse n < 10 318 (0.5) <.001 3.98 (2.06–7.70)
Hypertension 191 (40.5) 21 795 (33.0) .001 1.38 (1.15–1.66)
Liver disease 11 (2.3) 617 (0.9) .002 2.52 (1.39–4.59)
Malnutrition/weight loss 21 (4.4) 1234 (1.9) <.001 2.44 (1.57–3.77)
Obesity 82 (17.4) 7511 (11.4) <.001 1.64 (1.29–2.08)
Peripheral vascular disease n < 10 414 (0.6) .005 2.72 (1.35–5.47)
Pneumonia or urinary tract infection 26 (5.5) 2208 (3.3) .010 1.69 (1.14–2.51)
Psychoses 23 (4.9) 2139 (3.2) .047 1.53 (1.01–2.33)
Renal failure n < 10 219 (0.3) <.001 5.18 (2.58–10.43)
Smoking 74 (15.7) 8538 (12.9) .073 1.26 (0.98–1.61)
Smoking-related diseases 39 (8.3) 2371 (3.6) <.001 2.42 (1.74–3.36)
Staphylococcus aureus infection n < 10 85 (0.1) <.001 6.56 (2.45–17.55)
Operative Factors
Facility
Type of facility Inpatient hospital 166 (35.2) 10 798 (16.3) <.001 1.00
Outpatient hospital 188 (39.8) 38 711 (58.6) 0.32 (0.26–0.39)
ASC 20 (4.2) 4038 (6.1) 0.32 (0.20–0.51)
Missing facilityb or uncertain inpatient 
designationc
98 (20.8) 12 547 (19.0) 0.51 (0.40–0.65)
Number of beds 1–299 253 (53.6) 32 714 (49.5) .121 1.00
300–499 81 (17.2) 13 508 (20.4) 0.78 (0.60–1.00)
500+ 62 (13.1) 8728 (13.2) 0.92 (0.70–1.21)
ASC 20 (4.2) 4038 (6.1) 0.64 (0.41–1.01)
Missing facilityb 56 (11.9) 7106 (10.8) 1.02 (0.77–1.37)
Medical school affiliation Yes 175 (37.1) 22 267 (33.7) .140 1.16 (0.95–1.42)
No 221 (46.8) 32 683 (49.4) 1.00
ASC 20 (4.2) 4038 (6.1) 0.73 (0.46–1.16)
Missing facilityb 56 (11.9) 7106 (10.8) 1.17 (0.87–1.57)
Residency program Yes 142 (30.1) 17 126 (25.9) .063 1.23 (1.00–1.52)
No 254 (53.8) 37 824 (57.2) 1.00
ASC 20 (4.2) 4038 (6.1) 0.74 (0.47–1.17)
Missing facilityb 56 (11.9) 7106 (10.8) 1.18 (0.88–1.57)
Ownership Government 49 (10.4) 5594 (8.5) .178 1.00
Nongovernment, not for profit 303 (64.2) 42 194 (63.8) 0.82 (0.61–1.11)
Investor owned, for profit 44 (9.3) 7162 (10.8) 0.70 (0.47–1.05)
ASC 20 (4.2) 4038 (6.1) 0.57 (0.34–0.95)
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percent of SSIs were first identified 2–30  days postsurgery, 
12.9% between 31–60 days, and 5.7% between 61–90 days after 
the procedure. The incidence of SSI was significantly higher 
after an open (4.93% [51 of 1034]) versus laparoscopic chole-
cystectomy (0.64% [421 of 65 532]; P < .001). Overall, 63.1% of 
SSIs were serious. There was no significant difference between 
Table 2. Multivariable Cox Proportional Hazards Model of Significant Risk Factors for SSI After Cholecystectomy
Variable Category Adjusted Hazards Ratio (95% CI)
Patient Risk Factors
Male 1.42 (1.17–1.72)
Chronic anemia 2.46 (1.67–3.63)
Diabetes mellitus 1.53 (1.19–1.98)
Drug abuse 2.85 (1.46–5.54)
Malnutrition/weight loss 2.09 (1.34–3.25)
Obesity 1.39 (1.09–1.77)
Smoking-related diseases 1.63 (1.16–2.28)
Staphylococcus aureus infection 3.43 (1.26–9.31)
Operative Risk Factors
Type of facility Inpatient hospital 1.00
Outpatient hospital 0.57 (0.45–0.74)
ASC 0.65 (0.40–1.05)
Missing facility or uncertain inpatient hospital designationa 0.81 (0.62–1.06)
Surgical approach and acute cholecystitis/ 
obstruction
Laparoscopic approach without acute cholecystitis/obstruction 1.00
Laparoscopic approach with acute cholecystitis/obstruction 1.58 (1.27–1.96)
Laparoscopic converted to open approach without acute 
cholecystitis/obstruction
7.11 (3.87–13.08)
Laparoscopic converted to open approach with acute 
cholecystitis/obstruction
4.71 (2.74–8.10)
Planned open approach without acute cholecystitis/ 
obstruction
4.04 (1.96–8.34)
Planned open approach with acute cholecystitis/obstruction 4.29 (2.45–7.52)
ERCP/bile duct explorationb 2.08 (1.31–3.30)
Postoperative Risk Factors (Before SSI)
Chronic anemia 1.68 (1.12–2.53)
Pneumonia or urinary tract infection 2.15 (1.45–3.17)
Abbreviations: ASC, ambulatory surgery center; CI, confidence interval; ERCP, endoscopic retrograde cholangiopancreatography; SSI, surgical site infection.
aMissing facility type due to no match to a facility in the American Hospital Association Annual Survey of Hospitals or the IMS Health Outpatient Surgery Center Profiling Solution data or a 
match to multiple facilities. Uncertain inpatient admission due to inpatient designation based on a same-day nonfacility claim.
bERCP and bile duct exploration combined for multivariable model due to small cell counts.
Variable Category SSI n (%) No SSI  n (%) P Hazards Ratio (95% CI)
Cholecystectomy
Acute cholecystitis/obstruction 205 (43.4) 17 481 (26.4) <.001 2.13 (1.78–2.56)
Other/chronic cholecystitis 386 (81.8) 56 202 (85.0) .047 0.79 (0.62–1.00)
Choledocholithiasis 37 (7.8) 2652 (4.0) <.001 2.03 (1.45–2.84)
Surgical approach Laparoscopic approach 421 (89.2) 65 111 (98.5) <.001 1.00
Laparoscopic converted to open approach 28 (5.9) 507 (0.8) 8.48 (5.79–12.44)
Planned open approach 23 (4.9) 476 (0.7) 7.40 (4.87–11.26)
Endoscopic retrograde 
cholangiopancreatography
n < 10 302 (0.5) <.001 3.74 (1.86–7.52)
Bile duct exploration 12 (2.5) 426 (0.6) <.001 3.97 (2.24–7.04)
Postoperative Factors
Chronic anemia 33 (7.0) 1289 (2.0) <.001 3.76 (2.64–5.35)
Pneumonia or urinary tract infection 28 (5.9) 1386 (2.1) <.001 2.91 (1.99–4.27)
Abbreviations: ASC, ambulatory surgery center; CI, confidence interval; SSI, surgical site infection.
aThe following factors had P ≥ 0.2 and were excluded from the table: patient home urban/rural location, patient income quartile, alcohol abuse, cancer, coagulopathy, disease-modifying 
antirheumatic drugs or biologic drugs, oral corticosteroids, skin disease, total annual surgical procedures quartile for performing facility, facility urban/rural location, facility region of the 
United States, cholelithiasis, cholangiography, and other bile duct procedures.
bMissing facility type due to no match to a facility in the American Hospital Association Annual Survey of Hospitals or the IMS Health Outpatient Surgery Center Profiling Solution data or 
a match to multiple facilities.
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the proportion of serious SSIs that were early (within 30 days 
of surgery) compared with nonserious SSIs (83.9% [250 of 298] 
vs 77.0% [134 of  174], respectively; P  =  .064). Infection rates 
were similar for planned open and converted-to-open proce-
dures (4.61% [23 of 499] and 5.23% [28 of 535], respectively; 
P = .643).
Univariate risk factors for SSI are noted in Table  1. For 
the multivariable analysis, an interaction term was included 
in the model to analyze the impact of acute cholecystitis/
obstruction depending on the operative approach (Table 2). 
Patient-level risk factors for SSI included male gender, 
chronic anemia, diabetes mellitus, drug abuse, malnutri-
tion/weight loss, obesity, smoking-related diseases (eg, lung 
cancer, chronic obstructive pulmonary disease), and previ-
ous Staphylococcus aureus infection. Patients whose chole-
cystectomy was performed as an outpatient procedure at a 
hospital (HR 0.57) were at lower risk of SSI. Laparoscopic 
approach with acute cholecystitis/obstruction was associ-
ated with significantly increased risk of SSI compared with 
laparoscopic approach without acute cholecystitis (HR 1.58). 
Open cholecystectomy was associated with increased risk of 
SSI regardless of whether acute cholecystitis/obstruction was 
present (HR 4.29 and 4.04, respectively; P  =  .891 for post 
hoc comparison of the HRs). Conversion to open cholecys-
tectomy was also associated with similar risk of SSI, regard-
less of whether acute cholecystitis/obstruction was present 
(HR 4.71 and 7.11, respectively; post hoc P = .283). In addi-
tion, the HRs for SSI for planned open compared with con-
verted procedures were similar among those with (P = .796) 
and without (P  =  .217) acute cholecystitis/obstruction. 
Concurrent endoscopic retrograde cholangiopancreatog-
raphy (ERCP)/bile duct exploration, postoperative chronic 
anemia, and postoperative pneumonia/urinary tract infec-
tion were also associated with significantly higher risk of SSI 
post-cholecystectomy.
In a sensitivity analysis comparing early SSI only versus no 
SSI, risk factors were generally similar to the original model. 
Previous S aureus infection, ERCP/bile duct exploration, and 
postoperative chronic anemia dropped out of the model and 
were among the factors with the smallest number of patients 
with SSI. The general trends and magnitude of HRs in the early 
SSI model were similar to the total SSI model, and in all cases 
the HRs in the early SSI model were within the 95% confidence 
interval of the HR from the total SSI model.
In the second sensitivity analysis restricting the outcome to 
serious SSI versus no SSI, new risk factors included older age 
and choledocholithiasis. Obesity, smoking-related diseases, and 
ERCP/bile duct exploration were dropped from the model. The 
general trends and magnitude of HRs in the serious SSI model 
were similar to the total SSI model, and in all cases the HRs in 
the serious SSI model were within the 95% confidence interval 
of the HR from the total SSI model.
DISCUSSION
There are few published data on risk factors for SSI after chol-
ecystectomy, particularly after ambulatory procedures. Our 
study identifies new patient-, operative-, and postoperative risk 
factors for infection after cholecystectomy to the literature and 
confirms some risk factors identified in previous reports.
We found a 6-fold higher risk of SSI after open versus lap-
aroscopic cholecystectomy, consistent with previous findings 
[6–16]. The incidence of SSI after laparoscopic cholecystectomy 
converted to an open procedure was the same as the SSI inci-
dence after planned open cholecystectomy (5.23% and 4.61%, 
respectively). This contrasts with the finding of Bogdanic 
et al [13] who reported a higher SSI rate after laparoscopic to 
open conversion (17.9%) compared with open (6.1%) surgery, 
although only 28 operations in that study involved conversion. 
Two groups reported significantly increased risk of SSI after 
conversion from laparoscopic to open procedure compared 
with laparoscopic cholecystectomy, but neither study included 
planned open procedures [20, 31]. Our results suggest that 
in the present era, uncomplicated patients undergoing either 
planned or converted open cholecystectomy are at similar risk 
of SSI.
We found that acute cholecystitis or obstruction was associated 
with increased risk of surgical site infection after laparoscopic but 
not after open (planned or converted) cholecystectomy. This con-
trasts with the finding of Hussain and Khan [32] who reported 
no difference in the incidence of SSI in laparoscopic cholecystec-
tomy patients in Saudi Arabia with acute versus chronic chole-
cystitis (1.7% and 1.3%, respectively). In other studies restricted 
to laparoscopic cholecystectomy, Giger et al [33] found increased 
risk of postoperative local and systemic complications (includ-
ing SSI) with acute cholecystitis in multivariate analyses, whereas 
den Hoed et al [34] found an association in univariate analysis 
between acute cholecystitis and increased risk of SSI.
At the patient level, we found gender, chronic anemia, dia-
betes, drug abuse, malnutrition/weight loss, obesity, smoking- 
related diseases, and previous S aureus infection to be associated 
with increased risk of SSI. With the exception of diabetes [7], 
malnutrition [35], and male (vs female) gender [6, 7, 13], none of 
these conditions have been previously reported as independent 
risk factors for SSI after cholecystectomy. Men have also been 
shown to be at increased risk of conversion to open procedure 
[36–38] and intraoperative and postoperative local complica-
tions after cholecystectomy [33, 39]. In our study, men had more 
severe biliary disease compared with women, including higher 
proportions of men with acute cholecystitis or obstruction, 
choledocholithiasis, and open (planned or converted) opera-
tive approach (see Supplementary Appendix 3; data not shown). 
It is possible that the increased risk of SSI we found in men is 
due to residual confounding with increased severity of biliary 
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Limitations of our study include potential misclassification 
of diagnoses and likely undercoding of SSIs, especially minor 
infections diagnosed and treated only with oral antibiotics in 
outpatient settings during the 90-day global surgical reimburse-
ment period [40]. Thus, our calculations for the incidence of 
SSI after cholecystectomy are likely underestimates of the true 
SSI rates. We found that slightly more than half of open chol-
ecystectomy procedures were not planned, but due to the lim-
itations of our data source we were unable to determine why 
the conversion was necessary. In addition, our findings may not 
be generalizable to all patients undergoing cholecystectomy, 
because we limited our surgical population to less complex pro-
cedures in privately insured, nonelderly adults.
A major strength of our study is the large, geographically 
diverse nature of the patient population. Because of this, we iden-
tified many novel risk factors, including an interesting interaction 
between surgical approach and the presence of acute cholecystitis/
obstruction. In addition, we were able to compare the risk of SSI 
after open, converted to open and laparoscopic procedures, which 
has not been done previously. Because these data contain informa-
tion from numerous urban and rural ambulatory and hospital set-
tings, a wide variety of surgical practices are captured. In addition, 
we used longitudinal claims data to identify infections after dis-
charge across the full spectrum of care. This is particularly impor-
tant for procedures performed in ambulatory settings, because 
patients may be diagnosed and treated for SSIs at a facility other 
than where the surgery was performed. Another strength of our 
study is the robustness of our findings, because models restricted 
to early SSI and serious SSI yielded similar results.
CONCLUSIONS
The SSI risk factors we identified after cholecystectomy may be 
helpful for risk stratification to adjust for differences in patient 
mix between different facilities. This is important when compar-
ing SSI rates between institutions, because facilities may have dif-
fering proportions of complex cases requiring an open approach 
and patients with more severe gallbladder disease. Failure to 
account for this complexity in case mix may result in misclassify-
ing institutions as having a higher than expected rate of infection 
after cholecystectomy. In the current era of pay-for-performance 
and publicly reported healthcare-associated infection rates, 
this could have considerable negative impact for providers and 
facilities. Most importantly, understanding the relevant periop-
erative risk factors for infection will better inform patients and 
healthcare providers what to anticipate after this common surgi-
cal procedure and may allow targeted interventions in high-risk 
groups to reduce postoperative infections.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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